home / stock / renx / renx news

RENX News and Press, RELX N.V. American Depositary Shares (Each representing One) From 03/15/21

Stock Information
Company Name: RELX N.V. American Depositary Shares (Each representing One)
Stock Symbol: RENX
Market: NYSE
Menu
RENX RENX Quote RENX Short RENX News RENX Articles RENX Message Board
Get RENX Alerts

News, Short Squeeze, Breakout and More Instantly...
RENX - Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provide...
RENX - Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces t...

RENX - RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021

NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improv...

RENX - The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health

NEW YORK and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah , one of the top research institutions in the United States, today announce...
RENX - RenalytixAI to announce Financial Results for six and three months ended December 31, 2020

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to ...

RENX - American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health

NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseases to drive improved patient outcomes and advance value-based care, ann...

RENX - Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN: 0938-AT88 ), to provide a coverage pathway for Medicare beneficiaries nationwide to have fast...
RENX - Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chro...

RENX - RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announ...

RENX - RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today report...
Previous 10 Next 10